Literature DB >> 17609981

Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene.

Ratnesh Kumar Singh1, Dipanjana Indra, Sraboni Mitra, Ranajit Kumar Mondal, Partha Sarathi Basu, Anup Roy, Susanta Roychowdhury, Chinmay Kumar Panda.   

Abstract

The aim of this study was to locate the candidate tumor suppressor genes (TSGs) loci in the chromosomal 4p15-16, 4q22-23 and 4q34-35 regions associated with the development of uterine cervical carcinoma (CA-CX). Deletion mapping of the regions by microsatellite markers identified six discrete areas with high frequency of deletions, viz. 4p16.2 (D1: 40%), 4p15.31 (D2: 35-38%), 4p15.2 (D3: 37-40%), 4q22.2 (D4: 34%), 4q34.2-34.3 (D5: 37-59%) and 4q35.1 (D6: 40-50%). Significant correlation was noted among the deleted regions D1, D2 and D3. The deletions in D1, D2, D5 and D6 regions are suggested to be associated with the cervical intraepithelial neoplasia (CIN), and deletions in the D2, D3, D5 and D6 regions seems to be associated with progression of CA-CX. The deletions in the D2 and D6 regions showed significant prognostic implications (P = 0.001; 0.02). The expression of the candidate TSG SLIT2 mapped to D2 region gradually reduced from normal cervix uteri -->CIN --> CA-CX. SLIT2 promoter hypermethylation was seen in 28% CIN samples and significantly increased with tumor progression (P = 0.04). Significant correlation was seen between SLIT2 deletion and its promoter methylation (P = 0.001), indicating that both these phenomena could occur simultaneously to inactivate this gene. Immunohistochemical analysis showed reduced expression of SLIT2 in cervical lesions and CA-CX cell lines. Although no mutation was detected in the SLIT2 promoter region (-432 to + 55 bp), CC and AA haplotypes were seen in -227 and -195 positions, respectively. Thus, it indicates that inactivation of SLIT2-ROBO1 signaling pathway may have an important role in CA-CX development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609981     DOI: 10.1007/s00439-007-0375-6

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   5.881


  47 in total

1.  The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation.

Authors:  C Forcet; X Ye; L Granger; V Corset; H Shin; D E Bredesen; P Mehlen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.

Authors:  Ashraf Dallol; Nancy Fernandes Da Silva; Paolo Viacava; John D Minna; Ivan Bieche; Eamonn R Maher; Farida Latif
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

Review 3.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics.

Authors:  S B Baylin; J G Herman
Journal:  Trends Genet       Date:  2000-04       Impact factor: 11.639

4.  Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants.

Authors:  J B Sherwood; N Shivapurkar; W M Lin; R Ashfaq; D S Miller; A F Gazdar; C Y Muller
Journal:  Gynecol Oncol       Date:  2000-10       Impact factor: 5.482

Review 5.  Cancer epigenetics comes of age.

Authors:  P A Jones; P W Laird
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4.

Authors:  Nicholas R Forsyth; Vivienne Morrison; Nicola J Craig; Sara A Fitzsimmons; Nighean I Barr; Hazel Ireland; Katrina E Gordon; Sally Dowen; Andrew P Cuthbert; Robert F Newbold; Steven D Bryce; E Kenneth Parkinson
Journal:  Oncogene       Date:  2002-08-01       Impact factor: 9.867

8.  [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors].

Authors:  V I Loginov; A V Maliukova; Iu A Seregin; D S Khodyrev; T P Kazubskaia; V D Ermilova; R F Gar'kavtseva; L L Kiselev; E R Zabarovskiĭ; E A Braga
Journal:  Mol Biol (Mosk)       Date:  2004 Jul-Aug

9.  Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.

Authors:  M R Mullokandov; N G Kholodilov; N B Atkin; R D Burk; A B Johnson; H P Klinger
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

10.  SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.

Authors:  D Astuti; N F Da Silva; A Dallol; D Gentle; T Martinsson; P Kogner; R Grundy; T Kishida; M Yao; F Latif; E R Maher
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  29 in total

1.  Slits affect the timely migration of neural crest cells via Robo receptor.

Authors:  Dion Giovannone; Michelle Reyes; Rachel Reyes; Lisa Correa; Darwin Martinez; Hannah Ra; Gustavo Gomez; Joshua Kaiser; Le Ma; Mary-Pat Stein; Maria Elena de Bellard
Journal:  Dev Dyn       Date:  2012-06-23       Impact factor: 3.780

2.  Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis.

Authors:  Wei-Jie Zhou; Zhen H Geng; Shan Chi; Wenli Zhang; Xiao-Feng Niu; Shu-Jue Lan; Li Ma; Xuesong Yang; Li-Jing Wang; Yan-Qing Ding; Jian-Guo Geng
Journal:  Cell Res       Date:  2011-02-01       Impact factor: 25.617

3.  SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Chunhua Liu; Xuefei Shi; Li Wang; Ying Wu; Feiyan Jin; Cuiqing Bai; Yong Song
Journal:  Tumour Biol       Date:  2014-03-15

Review 4.  Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.

Authors:  Hongfei Jiang; Hang Hu; Xiaomei Tong; Qiuhong Jiang; Haiyan Zhu; Songying Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

Review 5.  Extracellular superoxide dismutase and its role in cancer.

Authors:  Brandon Griess; Eric Tom; Frederick Domann; Melissa Teoh-Fitzgerald
Journal:  Free Radic Biol Med       Date:  2017-08-24       Impact factor: 7.376

6.  Reduced expression of Slit2 in renal cell carcinoma.

Authors:  Wei-Jie Ma; Yu Zhou; Dan Lu; Dong Dong; Xiao-Jun Tian; Jie-Xi Wen; Jun Zhang
Journal:  Med Oncol       Date:  2013-11-15       Impact factor: 3.064

7.  Involvement of the SLIT/ROBO pathway in follicle development in the fetal ovary.

Authors:  Rachel E Dickinson; Lynn Hryhorskyj; Hannah Tremewan; Kirsten Hogg; Axel A Thomson; Alan S McNeilly; W Colin Duncan
Journal:  Reproduction       Date:  2009-11-09       Impact factor: 3.906

Review 8.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

9.  MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.

Authors:  Jun Tie; Yanglin Pan; Lina Zhao; Kaichun Wu; Jie Liu; Shiren Sun; Xuegang Guo; Biaoluo Wang; Yi Gang; Yongguo Zhang; Quanjiang Li; Taidong Qiao; Qingchuan Zhao; Yongzhan Nie; Daiming Fan
Journal:  PLoS Genet       Date:  2010-03-12       Impact factor: 5.917

10.  Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma.

Authors:  Hee Kyung Kim; Hong Zhang; Hui Li; Tsung-Teh Wu; Stephen Swisher; Donggou He; Lizhi Wu; Jianmin Xu; Craig A Elmets; Mohammad Athar; Xìao-chun Xu; Hui Xu
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.